Matches in SemOpenAlex for { <https://semopenalex.org/work/W2103754725> ?p ?o ?g. }
Showing items 1 to 82 of
82
with 100 items per page.
- W2103754725 endingPage "793" @default.
- W2103754725 startingPage "788" @default.
- W2103754725 abstract "This multicenter, double-blind study evaluated efficacy and safety of the vasopeptidase inhibitor omapatrilat, which simultaneously inhibits neutral endopeptidase and angiotensin converting enzyme, when given in conjunction with hydrochlorothiazide (HCTZ) to subjects nonresponsive to HCTZ alone. The study enrolled 657 subjects with mild to severe hypertension. After a 2-week placebo lead-in period and a 4-week HCTZ phase, 274 subjects were randomized to receive omapatrilat (10 or 20 mg, electively titrated to 20 or 40 mg, respectively, at week 4 if seated diastolic blood pressure [SeDBP] was > or =90 mm Hg) or matching placebo in addition to 25 mg of HCTZ as continuing therapy. The primary outcome measure was change in SeDBP from baseline to week 8. At week 8, placebo plus HCTZ-adjusted additional reductions in SeDBP in the omapatrilat 10/20 mg and 20/40 mg treatment groups (4 and 5 mm Hg, respectively) were significant (P < .001), as were changes in seated systolic blood pressure in both omapatrilat-treated groups (7 and 10 mm Hg, respectively; P < .001). Seated diastolic blood pressure was normalized (<90 mm Hg) in 38% of subjects in the placebo group compared to 59% and 64% of subjects in the omapatrilat groups (P < or = .008). Adverse events, serious adverse events, and discontinuations attributed to adverse events were infrequent. There were no clinically relevant changes in serum creatinine or potassium. Omapatrilat was effective and well tolerated when added to HCTZ in subjects whose blood pressure was not controlled with HCTZ alone." @default.
- W2103754725 created "2016-06-24" @default.
- W2103754725 creator A5004802491 @default.
- W2103754725 creator A5031601689 @default.
- W2103754725 creator A5039965133 @default.
- W2103754725 creator A5071877865 @default.
- W2103754725 creator A5074725986 @default.
- W2103754725 creator A5082475766 @default.
- W2103754725 date "2001-08-01" @default.
- W2103754725 modified "2023-10-16" @default.
- W2103754725 title "Efficacy and safety of omapatrilat with hydrochlorothiazide for the treatment of hypertension in subjects nonresponsive to hydrochlorothiazide alone" @default.
- W2103754725 cites W1982976741 @default.
- W2103754725 cites W1991900380 @default.
- W2103754725 cites W2001207362 @default.
- W2103754725 cites W2039673335 @default.
- W2103754725 cites W2059889873 @default.
- W2103754725 cites W2121926960 @default.
- W2103754725 cites W2127893485 @default.
- W2103754725 cites W3022929210 @default.
- W2103754725 doi "https://doi.org/10.1016/s0895-7061(01)01294-8" @default.
- W2103754725 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11497195" @default.
- W2103754725 hasPublicationYear "2001" @default.
- W2103754725 type Work @default.
- W2103754725 sameAs 2103754725 @default.
- W2103754725 citedByCount "17" @default.
- W2103754725 countsByYear W21037547252013 @default.
- W2103754725 countsByYear W21037547252014 @default.
- W2103754725 countsByYear W21037547252017 @default.
- W2103754725 crossrefType "journal-article" @default.
- W2103754725 hasAuthorship W2103754725A5004802491 @default.
- W2103754725 hasAuthorship W2103754725A5031601689 @default.
- W2103754725 hasAuthorship W2103754725A5039965133 @default.
- W2103754725 hasAuthorship W2103754725A5071877865 @default.
- W2103754725 hasAuthorship W2103754725A5074725986 @default.
- W2103754725 hasAuthorship W2103754725A5082475766 @default.
- W2103754725 hasBestOaLocation W21037547251 @default.
- W2103754725 hasConcept C126322002 @default.
- W2103754725 hasConcept C126894567 @default.
- W2103754725 hasConcept C142724271 @default.
- W2103754725 hasConcept C197934379 @default.
- W2103754725 hasConcept C204787440 @default.
- W2103754725 hasConcept C27081682 @default.
- W2103754725 hasConcept C2777097880 @default.
- W2103754725 hasConcept C2779918671 @default.
- W2103754725 hasConcept C2780361556 @default.
- W2103754725 hasConcept C42219234 @default.
- W2103754725 hasConcept C71924100 @default.
- W2103754725 hasConcept C84393581 @default.
- W2103754725 hasConceptScore W2103754725C126322002 @default.
- W2103754725 hasConceptScore W2103754725C126894567 @default.
- W2103754725 hasConceptScore W2103754725C142724271 @default.
- W2103754725 hasConceptScore W2103754725C197934379 @default.
- W2103754725 hasConceptScore W2103754725C204787440 @default.
- W2103754725 hasConceptScore W2103754725C27081682 @default.
- W2103754725 hasConceptScore W2103754725C2777097880 @default.
- W2103754725 hasConceptScore W2103754725C2779918671 @default.
- W2103754725 hasConceptScore W2103754725C2780361556 @default.
- W2103754725 hasConceptScore W2103754725C42219234 @default.
- W2103754725 hasConceptScore W2103754725C71924100 @default.
- W2103754725 hasConceptScore W2103754725C84393581 @default.
- W2103754725 hasIssue "8" @default.
- W2103754725 hasLocation W21037547251 @default.
- W2103754725 hasLocation W21037547252 @default.
- W2103754725 hasOpenAccess W2103754725 @default.
- W2103754725 hasPrimaryLocation W21037547251 @default.
- W2103754725 hasRelatedWork W131083658 @default.
- W2103754725 hasRelatedWork W1552208713 @default.
- W2103754725 hasRelatedWork W1990971120 @default.
- W2103754725 hasRelatedWork W2051184959 @default.
- W2103754725 hasRelatedWork W2351940717 @default.
- W2103754725 hasRelatedWork W2352978680 @default.
- W2103754725 hasRelatedWork W2415791936 @default.
- W2103754725 hasRelatedWork W4230204649 @default.
- W2103754725 hasRelatedWork W4240368678 @default.
- W2103754725 hasRelatedWork W94256357 @default.
- W2103754725 hasVolume "14" @default.
- W2103754725 isParatext "false" @default.
- W2103754725 isRetracted "false" @default.
- W2103754725 magId "2103754725" @default.
- W2103754725 workType "article" @default.